ライフサイエンスコーパス: radical cystectomy

1 invasive disease continues to be managed by radical cystectomy.

2 ribing initial experiences with laparoscopic radical cystectomy.

3 ict the 5-year disease recurrence risk after radical cystectomy.

4 l volumes are markers of improved outcome of radical cystectomy.

5 can be determined before, during, and after radical cystectomy.

6 dvanced bladder cancer who were treated with radical cystectomy.

7 been shown to correlate with survival after radical cystectomy.

8 muscle-invasive bladder cancer who received radical cystectomy.

9 dvanced bladder cancer who were treated with radical cystectomy.

10 tine, doxorubicin, and cisplatin followed by radical cystectomy.

11 stage T2 to T4a) and were to be treated with radical cystectomy.

12 resection bladder tumor, most still require radical cystectomy.

13 of the bladder from patients that underwent radical cystectomy.

14 invasive carcinoma of the urinary bladder is radical cystectomy.

15 5 had a partial cystectomy, and 17 elected a radical cystectomy.

16 rapy who were unable or unwilling to undergo radical cystectomy.

17 les of ddMVAC were administered, followed by radical cystectomy.

18 e care and counseling of patients undergoing radical cystectomy.

19 ave been utilized to measure HRQOL following radical cystectomy.

20 er is an important outcome measure following radical cystectomy.

21 catheterizable urinary reservoirs following radical cystectomy.

22 ent of pelvic lymphadenectomy at the time of radical cystectomy.

23 nce supporting the use of minimally invasive radical cystectomy.

24 eed for curative therapeutic alternatives to radical cystectomy.

25 propriate timing of intravesical therapy and radical cystectomy.

26 ill sustain a complication within 90 days of radical cystectomy.

27 at RARC is an acceptable alternative to open radical cystectomy.

28 s an emerging minimally invasive approach to radical cystectomy.

29 ions and abstracts related to robot-assisted radical cystectomy.

30 guide the scientific practice of LND during radical cystectomy.

31 n-based combination chemotherapy followed by radical cystectomy.

32 as improved convalescence compared with open-radical cystectomy.

33 toperative complications with robot-assisted radical cystectomy.

34 erm oncologic outcomes as compared with open radical cystectomy.

35 provided a retrospective comparison to open radical cystectomy.

36 reproducible, minimally invasive approach to radical cystectomy.

37 to determine the stage of the disease before radical cystectomy.

38 ances and outcomes related to robot-assisted radical cystectomy.

39 could be spared the unnecessary morbidity of radical cystectomy.

40 ay help in making treatment decisions before radical cystectomy.

41 ssary, can achieve survival rates similar to radical cystectomy.

42 Of these 2 patients, one required radical cystectomy.

43 nt strategies particularly as they relate to radical cystectomy.

44 for management of muscle invasive disease is radical cystectomy.

45 rm oncologic outcomes compare well with open radical cystectomy.

46 Of the 17 patients who had radical cystectomy, 11 (65%) are alive.

47 mproved our understanding of HRQOL following radical cystectomy, a lack of prospective studies limits

48 sputed benefit of adjuvant chemotherapy over radical cystectomy alone for muscle-invasive bladder can

49 In cisplatin-ineligible patients, radical cystectomy alone is recommended.

50 nsive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate

51 As compared with radical cystectomy alone, the use of neoadjuvant methotr

52 ated favorable clinical outcomes relative to radical cystectomy alone.

53 radual growth and experience in laparoscopic radical cystectomy, along with continuing refinements in

54 re was no evidence of an interaction between radical cystectomy and age, sex, comorbidity score, or c

55 immediate versus deferred chemotherapy after radical cystectomy and bilateral lymphadenectomy for pat

56 oncological outcomes of patients treated by radical cystectomy and bilateral lymphadenectomy for uro

57 se or node positive (pN1-3) M0 disease after radical cystectomy and bilateral lymphadenectomy, with n

58 techniques has prompted interest in robotic radical cystectomy and extended PLND, and recent reports

59 rioperative morbidity following contemporary radical cystectomy and identify preoperative, intraopera

60 We assessed whether radical cystectomy and intestinal urinary diversion are

61 omized comparison between minimally invasive radical cystectomy and open radical cystectomy is needed

62 inblastine, doxorubicin, and cisplatin) plus radical cystectomy and pelvic lymph node dissection.

63 Radical cystectomy and pelvic lymphadenectomy (PLND) rem

64 ce, minimally invasive techniques to perform radical cystectomy and PLND have been adopted.

65 r cancer consisting of patients treated with radical cystectomy and PLND.

66 We evaluated the association between radical cystectomy and risk of fracture at any site, con

67 d recovery protocols for patients undergoing radical cystectomy and urinary diversion and describe ou

68 Patients with bladder cancer who have radical cystectomy and urinary diversion are at increase

69 ate (radical prostatectomy), bladder cancer (radical cystectomy and urinary diversion for muscle inva

70 Radical cystectomy and urinary diversion may cause chron

71 n cystectomy are lacking, minimally invasive radical cystectomy appears to have superior perioperativ

72 dical prostatectomy and reconstruction after radical cystectomy are discussed.

73 long-term outcomes after minimally invasive radical cystectomy are limited, intermediate term oncolo

74 rospective, randomized comparisons with open radical cystectomy are needed as this technique continue

75 , randomized prospective comparisons to open radical cystectomy are needed to further validate this p

76 for the extirpative portion of laparoscopic radical cystectomy at multiple institutions.

77 Morbidity is common following radical cystectomy, but careful attention to preoperativ

78 el function in those undergoing laparoscopic radical cystectomy, but these observations have not been

79 ithin the last year, numerous robot-assisted radical cystectomy case series with larger cohorts have

80 While radical cystectomy cures many patients with this tumor,

81 Institutional radical cystectomy databases containing detailed informa

82 randomized trial comparing open and robotic radical cystectomy demonstrated equivalent lymph node yi

83 timately affect treatment as feasibility for radical cystectomy depends on staging by a combination o

84 , CMT can be considered as an alternative to radical cystectomy, especially in elderly patients not w

85 ients with lymph node-positive disease after radical cystectomy, even in the context of adjuvant chem

86 derwent bilateral pelvic lymphadenectomy and radical cystectomy for bladder cancer (median follow-up,

87 th-related quality of life (HRQOL) following radical cystectomy for bladder cancer is an important ou

88 Minimally invasive radical cystectomy for bladder cancer is performed lapar

89 rongly suggests that all patients undergoing radical cystectomy for bladder cancer should undergo con

90 er nomogram predicting recurrence risk after radical cystectomy for bladder cancer.

91 orodeoxyglucose (FDG) in patients undergoing radical cystectomy for cT2-3N0M0 urothelial carcinoma of

92 RREB1 expression and overall survival after radical cystectomy for invasive bladder cancer.

93 as a minimally invasive alternative to open radical cystectomy for the treatment of bladder cancer.

94 mph node dissection performed at the time of radical cystectomy has an ability to improve locoregiona

95 d therapeutic role of lymphadenectomy during radical cystectomy has become apparent and recent work h

96 However, the risk of fractures after radical cystectomy has not been defined.

97 Perioperative outcomes are as good as open radical cystectomy if not better.

98 inning to emerge and appears similar to open-radical cystectomy in nonrandomized comparisons.

99 splatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 uro

100 tine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminati

101 h there are limited data on robotic assisted radical cystectomy, initial reports suggest that an appr

102 Pelvic lymph node dissection at the time of radical cystectomy is a crucial component of the surgica

103 Radical cystectomy is a morbid procedure with rather lon

104 Robot-assisted radical cystectomy is a reproducible, minimally invasive

105 Robot-assisted radical cystectomy is an emerging minimally invasive app

106 Laparoscopic radical cystectomy is being increasingly performed at se

107 Robot-assisted radical cystectomy is being more widely studied as a pot

108 nimally invasive radical cystectomy and open radical cystectomy is needed to define the role of these

109 nuing refinements in technique, laparoscopic radical cystectomy is now being performed at many center

110 Robot-assisted radical cystectomy is steadily growing with a feasible l

111 The prevalence of robot-assisted radical cystectomy is steadily increasing.

112 Minimally invasive radical cystectomy is technically feasible.

113 Radical cystectomy is the standard of care for patients

114 008, and it is superseding pure laparoscopic radical cystectomy (LRC) at centers, where robot is avai

115 Radical cystectomy may include resection of adjacent org

116 e oncological efficacy of minimally invasive radical cystectomy (MIRC) and PLND.

117 mary tumor burden, defined as the receipt of radical cystectomy or >/= 50 Gy of radiation therapy del

118 bladder cancer, 151 were treated by standard radical cystectomy or by definitive TUR, if restaging TU

119 al therapy of his primary bladder tumor with radical cystectomy or radiation.

120 Open radical cystectomy (ORC) and pelvic lymph node dissectio

121 Although the added benefits of radical cystectomy over simple cystectomy alone are acce

122 ladder cancer outcome in patients undergoing radical cystectomy, p53 is the strongest predictor, foll

123 tic aneurysm repair, carotid endarterectomy, radical cystectomy, pancreatic resection, and esophagect

124 er of altered markers in patients treated by radical cystectomy provides prognostic information that

125 l principles for technique of robot-assisted radical cystectomy (RARC) based on current peer reviewed

126 Robot-assisted radical cystectomy (RARC) continues to provide a minimal

127 opments and current status of robot-assisted radical cystectomy (RARC) with pelvic lymphadenectomy (P

128 Although radical cystectomy (RC) currently is viewed as the stand

129 undergo neoadjuvant chemotherapy followed by radical cystectomy (RC).

130 urologic cancer-related surgical procedures (radical cystectomy [RC], radical nephrectomy [RN], and r

131 ng-term oncologic outcomes with laparoscopic radical cystectomy remain undefined, and appropriate lym

132 Radical cystectomy remains the gold-standard therapy for

133 .), management guidelines are less clear and radical cystectomy remains the mainstay of treatment at

134 While radical cystectomy remains the mainstay of treatment for

135 Optimal outcomes following radical cystectomy require an extended lymph node dissec

136 s examined immunohistochemically on archival radical cystectomy samples from 164 patients with invasi

137 s, with rates of overall survival similar to radical cystectomy series.

138 appear to be equivalent to contemporary open radical cystectomy series.

139 nal and oncologic outcome data, laparoscopic radical cystectomy should be considered an investigative

140 oncologic outcomes appear comparable to open radical cystectomy, the reference standard.

141 ted for early aggressive intervention (i.e., radical cystectomy), then treatment recommendations shou

142 iew the current experience with laparoscopic radical cystectomy to identify its role in oncological b

143 dequate lymph node dissection at the time of radical cystectomy to optimize oncologic outcomes.

144 Radical cystectomy with an appropriate lymph node dissec

145 All patients undergoing radical cystectomy with bilateral pelvic iliac lymphaden

146 Radical cystectomy with bilateral pelvic lymph node diss

147 sive disease in the United States centers on radical cystectomy with bilateral pelvic lymphadenectomy

148 Laparoscopic radical cystectomy with extended lymphadenectomy provide

149 findings regarding the clinical benefits of radical cystectomy with extended lymphadenectomy, and wi

150 verall survival rates in patients undergoing radical cystectomy with extended PLND, even in cases of

151 cles of AMVAC with pegfilgrastim followed by radical cystectomy with lymph node dissection.

152 adder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers

153 Radical cystectomy with pelvic lymph node dissection (PL

154 n-based neoadjuvant chemotherapy followed by radical cystectomy with pelvic lymph node dissection, wh

155 assess the current status of robot-assisted radical cystectomy with pelvic lymphadenectomy and urina

156 Radical cystectomy with thorough pelvic lymphadenectomy

157 Robot-assisted radical cystectomy with urinary diversion appears to be